Dr. Heike Oberwittler

Interim Chief Medical Officer

Dr. Heike Oberwittler is a MD by training, with a specialization in clinical pharmacology. She received her medical degree from the University of Heidelberg, Germany, and has over 20 years of experience in clinical trials and translational medicine in both academic environment sand pharmaceutical industry. Her expertise spans all phases of drug development across multiple therapeutic areas, including cardiology, rheumatology and oncology, with a focus on oncology for more than 10 years.

Prior to joining ITM in 2023, Dr. Oberwittler held management positions at Ipsen and Servier. At Ipsen, she led early clinical development, clinical pharmacokinetics and translational medicine. At Servier, she played a key role in building the early development group in oncology, serving as a head of clinical and project leaders in early drug development and as a member of the oncology leadership team.